^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET mutation

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    4d
    A retrospective study of PD-1 monoclonal antibody combined with nab-paclitaxel plus bevacizumab in the treatment of advanced malignant melanoma (PubMed, Zhonghua Zhong Liu Za Zhi)
    Patients received combination therapy with nab-paclitaxel, bevacizumab, and toripalimab (Q3W) at Nanjing Drum Tower Hospital. Furthermore, this triplet therapy combined with radiotherapy significantly improves PFS. Preliminary biomarker analysis suggests that patients with liver metastasis, MET or NF1 mutations may be less likely to benefit from this treatment regimen.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • NF1 (Neurofibromin 1)
    |
    MET mutation
    |
    Avastin (bevacizumab) • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    5d
    BNT326-02: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=420, Recruiting, BioNTech SE
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • PD-L1 negative • RET mutation • MET mutation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pumitamig (BNT327) • BNT326 • MK-3475 SC
    7d
    Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients. (PubMed, Lung Cancer)
    Vebreltinib plus an EGFR-TKI demonstrates favorable efficacy and manageable safety in real-world NSCLC patients with MET-driven resistance, with notable intracranial activity. Immunohistochemistry 3 + may serve as a practical predictive biomarker.
    Journal • Real-world evidence
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • MET overexpression • MET mutation • MET expression
    |
    vebreltinib (APL-101)
    8d
    Age-Associated Targetable Genomic Alterations and PD-L1 Expression in 2509 Patients With Pulmonary Ground-Glass Opacities. (PubMed, Cancer Med)
    GGOs exhibit a distinct genomic and PD-L1 profile with significant age-related heterogeneity, providing insights for age-stratified therapeutic strategies.
    Retrospective data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • HER-2 mutation • ALK rearrangement • TMB-L • RET mutation • MET mutation • RET rearrangement
    9d
    Analysis of Somatic Mutations and Immunotherapy Biomarkers in Chinese Patients With Non-Small Cell Lung Cancer During 2019-2024: A Retrospective Study. (PubMed, Health Sci Rep)
    TP53 mutations were more prevalent in males (p = 0.03) and associated with squamous cell carcinomas (p = 0.007), whereas EGFR mutations were more common in females (p < 0.001) and associated with lung adenocarcinomas (p = 0.029). Our findings suggest that a high TMB combined with a heterozygous HLA-I genotype serves as an effective biomarker for predicting the efficacy of immunotherapy in Chinese patients with NSCLC.
    Retrospective data • Journal • Tumor mutational burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PI3K (Phosphoinositide 3-kinases)
    |
    TP53 mutation • EGFR mutation • TMB-H • NRAS mutation • PTEN mutation • TMB-L • MET mutation • PDGFRA mutation
    9d
    Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report. (PubMed, J Thorac Oncol)
    Amivantamab-lazertinib reduces common resistance mechanisms (e.g., EGFR/MET) versus osimertinib, suggesting that this regimen is changing the underlying biology of EGFR-mutant disease, contributing to both first- and second-line long-term efficacy outcomes.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • RB1 (RB Transcriptional Corepressor 1)
    |
    EGFR mutation • MET amplification • MET mutation
    |
    Guardant360® CDx
    |
    Tagrisso (osimertinib) • Lazcluze (lazertinib)
    10d
    A Phase II Study of GC101 in NSCLC (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Shanghai Juncell Therapeutics
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • MET exon 14 mutation • RET mutation • MET mutation • KRAS G12 • EGFR negative • NTRK fusion
    |
    GC101 TIL
    10d
    ATATcH Alternating Treatment Plans for Advanced Cancer (clinicaltrials.gov)
    P2, N=150, Recruiting, Rutgers, The State University of New Jersey | Trial completion date: Dec 2025 --> May 2028 | Trial primary completion date: May 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed
    15d
    POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation • MET mutation
    |
    Keytruda (pembrolizumab) • Tepmetko (tepotinib)
    16d
    Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • MET amplification • ALK rearrangement • MET exon 14 mutation • MET overexpression • ROS1 rearrangement • MET mutation • KRAS G12 • ALK negative
    |
    vebreltinib (APL-101)
    17d
    Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC (ChiCTR2600121611)
    P4, N=535, Recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • ALK positive • RET fusion • ALK fusion • FGFR mutation • RET mutation • ROS1 fusion • MET mutation • RB1 mutation • NRG1 fusion • KRAS G12 • BRCA mutation
    |
    Ivesa (firmonertinib)
    17d
    A prospective, randomized, double-arm, multi-center, phase II study to Investigate the Efficacy and Safety of Sintilimab in Combination with IpilimumabN01 and Chemotherapy in First-line Treatment of driver gene-negative advanced NSCLC with PDL1 TPS<1% (ChiCTR2600119741)
    P2, N=80, PLA General Hospital; PLA General Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • HER-2 mutation • ALK mutation • ROS1 fusion • MET mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yervoy (ipilimumab) • Tyvyt (sintilimab) • pemetrexed